Table 3.
Characteristics of patients with exercise induced changes.
| Patient | Ejection Fraction | Ic Drug | Daily Total Dose (mg) | Peak HR on Treadmill (bpm) | ECG changes during exercise |
|---|---|---|---|---|---|
| 1 | 60 | flecainide | 200 | 162 | NSVT |
| 2 | 53 | flecainide | 200 | 158 | WCT |
| 3 | 55 | flecainide | 200 | 193 | QRS prolongation |
| 4 | 60 | flecainide | 200 | 142 | QRS prolongation |
| 5 | 65 | flecainide | 150 | 157 | QRS prolongation |
| 6 | 60 | flecainide | 200 | 131 | QRS prolongation |
| 7 | 55 | flecainide | 200 | 88 | NSVT |
| 8 | 55 | flecainide | 300 | 92 | NSVT |
| 9 | 60 | flecainide | 200 | 146 | ischemic changes |
| 10 | 60 | propafenone | 450 | 129 | NSVT |
| 11 | 45 | propafenone | 450 | 136 | QRS prolongation |
| 12 | 45 | propafenone | 450 | 166 | QRS prolongation |
| 13 | 60 | propafenone | 675 | 157 | QRS prolongation |
| 14 | 60 | propafenone | 450 | 122 | QRS prolongation |
| 15 | 65 | propafenone | 675 | 158 | QRS prolongation |
QRS prolongation defined as ≥ 25% increase of QRS duration compared to baseline ECG recording. Abbreviations: HR = heart rate; NSVT = non-sustained ventricular tachycardia; WCT = wide complex tachycardia.